Full Press Release Details
The IGC Executive Summary, dated May 25, 2017 can be viewed in PDF format by clicking here: ex99-1.pdf
A Leader in Cannabis-Based Combination Therapies
Develop, patent, test, and commercialize cannabis-based pharmaceutical, nutraceutical, and veterinary medicines.
Cannabis molecules (THC, CBD, CBN, CBG, terpenes etc.) activate over 60 known molecular pathways in the human body. Legal complications and misunderstanding have led to a vacuum in research and development, creating openings for biopharma entrepreneurs to occupy. Opportunities exist for breakthroughs in the treatment of pain, neurological disorders, eating disorders, and mood disorders using cannabis molecules.
Some of the most exciting products IGC is developing target the Alzheimer's, Parkinson's and pain markets.
Example Revenue Potential Breakdown:
IGC Parkinson's Suite
Primary Product: IGC-PK1
Secondary Parkinson's Products
WHERE DID IGC START?
We have been developing patentable cannabinoid products since 2014, focusing on combination therapy and veterinary medicine.
WHERE IS IGC RIGHT NOW?
COMPARATIVE VALUATION
IGC is on the NYSE MKT. Companies trading on OTC with much smaller product pipelines have similar valuations while those with similar sized pipelines have much higher valuations.
Nemus Bioscience (OTC: NMUS) $9.1M
India Globalization Capital (NYSE MKT: IGC) $11M
PharmaCyte Biotech (OTC: PMCB) $58M
Axim Biotechnologies Inc. (OTC: AXIM) $401M